Which dual antiplatelet therapy (DAPT) regimen is recommended for a patient with a mild non‑cardioembolic ischemic stroke or high‑risk transient ischemic attack?

DAPT for Code Stroke: Aspirin Plus Clopidogrel

For patients with acute minor non-cardioembolic ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), initiate dual antiplatelet therapy with aspirin plus clopidogrel within 12-24 hours of symptom onset and continue for 21 days, followed by single antiplatelet therapy. 1

Recommended Regimen

The 2021 AHA/ASA guideline provides the strongest recommendation (Class 1, Level A-SR) for:

• Aspirin plus clopidogrel started early (ideally within 12-24 hours, at least within 7 days)
• Duration: 21 to 90 days, then transition to single antiplatelet therapy
• Patient criteria: Minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4) 1

The most recent network meta-analysis from 2025 confirms that 21-day DAPT with aspirin-clopidogrel has the best risk-benefit profile among all short-course DAPT regimens 2. This is further supported by 2026 time-course analysis showing the greatest ischemic benefit occurs in week 1, with the benefit-to-risk ratio most favorable at 12.87 in the first week, dropping sharply to 1.68 in weeks 2-3 3.

Alternative Regimen (Use With Caution)

Aspirin plus ticagrelor for 30 days may be considered (Class 2a, Level B-RSR) for:

• Recent stroke (<24 hours) with NIHSS ≤5
• High-risk TIA (ABCD2 ≥6)
• Symptomatic intracranial or extracranial stenosis ≥30%

However, this combination significantly increases bleeding risk, including intracranial hemorrhage 1. Multiple 2025-2026 meta-analyses confirm aspirin-ticagrelor carries substantially higher major bleeding risk (OR 3.98-4.50) compared to aspirin-clopidogrel 2, 4, 5.

Critical Timing Considerations

Initiation window matters significantly:

• Optimal benefit when started within 12-24 hours 1
• Can be initiated up to 7 days, but efficacy diminishes 1
• Recent evidence from 2025 shows DAPT initiated within 72 hours reduces stroke recurrence (RR 0.77) 6
• Week-by-week analysis demonstrates ischemic benefit concentrated in first week, with diminishing efficacy thereafter 3

Duration: Why Not Longer?

Do not continue DAPT beyond 90 days (Class 3, Level A-SR) 1. The evidence is clear:

• Short-duration DAPT (≤90 days): Reduces recurrent stroke (RR 0.68) without significant bleeding increase (RR 1.88, not statistically significant) 7
• Long-duration DAPT (>90 days): No stroke reduction benefit (RR 0.89) but significantly increased major bleeding (RR 2.42) 7
• Continuous DAPT >90 days is associated with excess hemorrhage risk 1

Bleeding Risk Profile

DAPT increases bleeding complications across all regimens:

• Major bleeding: Overall RR 2.19-2.20 4, 6
• Hemorrhagic stroke: RR 2.08-2.09 4, 6
• Bleeding risk elevated primarily in weeks 1-2 3
• Aspirin-clopidogrel: More favorable bleeding profile than aspirin-ticagrelor 2

Expanded Indications (Mild-to-Moderate Stroke)

Recent 2025-2026 evidence extends DAPT benefits to NIHSS ≤5 (not just ≤3):

• Multiple meta-analyses confirm efficacy in mild-to-moderate strokes 8, 6
• Benefit consistent across stroke severity when initiated within 72 hours 8
• This represents an evolution beyond the original guideline's NIHSS ≤3 threshold

Common Pitfalls to Avoid

1. Do not use DAPT for cardioembolic stroke - anticoagulation is preferred 1
2. Do not increase aspirin dose or switch agents if patient already on aspirin at time of stroke - effectiveness not established 1
3. Do not use triple antiplatelet therapy - associated with excess hemorrhage 1
4. Do not continue beyond 90 days - bleeding risk outweighs benefit 1, 7
5. Do not delay initiation - benefit greatest when started within 12-24 hours 1, 3

Practical Algorithm

Step 1: Confirm eligibility

• Non-cardioembolic stroke
• NIHSS ≤3 (or ≤5 based on recent evidence)
• OR high-risk TIA (ABCD2 ≥4)
• Within 7 days of symptom onset (ideally <24 hours)

Step 2: Choose regimen

• First-line: Aspirin + clopidogrel (loading dose: aspirin 150-300 mg + clopidogrel 300-600 mg, then aspirin 75-100 mg + clopidogrel 75 mg daily)
• Alternative (if intracranial stenosis or ABCD2 ≥6): Consider aspirin + ticagrelor for 30 days, but weigh higher bleeding risk

Step 3: Duration

• Continue for 21 days (optimal risk-benefit) 2
• May extend to 90 days in very high-risk patients
• Then transition to single antiplatelet therapy

Step 4: Transition

• After 21-90 days, switch to clopidogrel 75 mg daily OR aspirin 50-325 mg daily OR aspirin 25 mg + extended-release dipyridamole 200 mg twice daily 1